Status:
COMPLETED
PRIZE ET Sub-Study
Lead Sponsor:
Papworth Hospital NHS Foundation Trust
Collaborating Sponsors:
NHS Greater Glasgow and Clyde
Conditions:
Microvascular Angina
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
Microvascular angina (MVA) is caused by abnormalities of the small blood vessels in the heart. Endothelin-1 (ET-1) is a chemical messenger that circulates and accumulates in the blood vessel walls, ca...
Detailed Description
Patients with microvascular angina (MVA) are under-diagnosed and have limited therapeutic options available to them. Endothelin-1 (ET-1) is a potent vasoconstrictor implicated in the small vessel obst...
Eligibility Criteria
Inclusion
- Patients who after screening blood tests and clinical assessment are ineligible for the main PRIZE trial will qualify for this study. Patients will be screened for the PRIZE trial according to the following:
- Inclusion criteria:
- Age \>18 years.
- Probable or definite Microvascular Angina as defined in COVADIS criteria:
- Clinical symptoms of angina
- No obstructive coronary artery disease
- Objective evidence of myocardial ischemia
- Evidence of impaired coronary microvascular function (Optional)
- Able to comply with study procedures.
- Screen failure for the main PRIZE study
- Written informed consent.
- Exclusion criteria:
- 1\. Lack of informed consent for the PRIZE ET Sub-study
Exclusion
Key Trial Info
Start Date :
May 14 2021
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
August 13 2022
Estimated Enrollment :
26 Patients enrolled
Trial Details
Trial ID
NCT04508998
Start Date
May 14 2021
End Date
August 13 2022
Last Update
April 4 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Royal Papworth Hospital NHS Foundation Trust
Cambridge, United Kingdom, CB2 0AY